# US 2021/0171498 A1 · Therapeutic compounds

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0171498 A1
- Document ID: US20210171498A1
- Status: Published application
- Kind: A1
- Application number: 17/062,676
- Filed: 2020-10-05
- Published: 2021-06-10
- Earliest claimed: 2018-02-15
- Assignees: Gilead Sciences, Inc.
- Applicants: Gilead Sciences, Inc.
- Inventors: Gediminas Brizgys; Eda Canales; Chienhung Chou; Michael Graupe; Jiayao Li; Roland D. Saito; Scott D. Schroeder; Winston C. Tse; Qiaoyin Wu; Jennifer R. Zhang
- Web page: https://patentgrep.com/patent/US20210171498A1

## CPC

- C07D 401/14: containing three or more hetero rings
- A61P 31/18: for HIV
- C07D 405/14: containing three or more hetero rings
- C07D 413/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The invention provides compounds having Formula (I): or a pharmaceutically acceptable salt thereof, as well as pharmaceutical compositions comprising the same, processes for their preparation, and methods of treating and preventing HIV infection by their administration.

## Claims

### Claim 1

A compound of formula I:
wherein
A is 3-6 membered carbocycle;
n is 0, 1, or 2;
m is 0, 1, or 2;
R1 is
each Z1 is independently (C1-C6)alkyl, (C3-C7)carbocycle, halogen, or —CN, wherein any (C1-C6)alkyl or (C3-C7)carbocycle of Z1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z1a groups, wherein the Z1a groups are the same or different;
each Z1a is independently halogen, (C3-C7)carbocycle, —OH, or —CN;
R2 is hydrogen, halogen, —OH, or —CN;
R3 is (C1-C6)alkyl or 3-5 membered heterocycle, wherein the (C1-C6)alkyl is unsubstituted or substituted with 1, 2, or 3 halogen atoms;
R4 is hydrogen, —S(O)2—(C1-C6)alkyl, —S(O)2—(C3-C6)carbocycle, or 5-6 membered heteroaryl, wherein any —S(O)2—(C1-C6) alkyl, —S(O)2-(C3-C6)carbocycle, or 5-6 membered heteroaryl of R4 is unsubstituted or substituted with 1, 2, or 3 Z2 groups, wherein the Z2 groups are the same or different;
Z2 is (C1-C6)alkyl or (C3-C6)carbocycle, wherein any (C1-C6)alkyl or (C3-C6)carbocycle is unsubstituted or substituted with 1, 2, or 3 Z2a groups, wherein the Z2a groups are the same or different;
Z2a is hydroxyl or halogen;
R5 is hydrogen or halogen; and
R6 is (C1-C3)alkyl;
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is a compound of formula Ia:
wherein:
n is 0, 1, or 2;
m is 0 or 1;
each Z1 is independently (C1-C6)alkyl, (C3-C7)carbocycle, or halogen, wherein any (C1-C6)alkyl or (C3-C7)carbocycle of Z1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z1a groups, wherein the Z1a groups are the same or different;
each Z1a is independently halogen or (C3-C7)carbocycle;
R2 is hydrogen or iodide;
R3 is (C1-C2)alkyl or 3-5 membered heterocycle, wherein the (C1-C2)alkyl is unsubstituted or substituted with 2 or 3 halogen atoms;
R4 is hydrogen, —S(O)2—(C1-C2)alkyl, —S(O)2-cyclopropyl, or 5-membered heteroaryl, wherein any —S(O)2—(C1-C2)alkyl, —S(O)2-cyclopropyl, or 5-membered heteroaryl of R4 is unsubstituted or substituted with 1, 2, or 3 Z2 groups, wherein the Z2 groups are the same or different;
Z2 is (C1-C3)alkyl or cyclopropyl, wherein any (C1-C3)alkyl or cyclopropyl is unsubstituted or substituted with 1, 2, or 3 Z2a groups, wherein the Z′ groups are the same or different;
Z2a is hydroxyl or fluorine;
R5 is hydrogen, chorine, or fluorine; and
R6 is (C1-C3)alkyl.

### Claim 3 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
n is 0, 1, or 2;
m is 0 or 1;
each Z1 is independently (C1-C6)alkyl, (C3-C7)carbocycle, or halogen, wherein any (C1-C6)alkyl or (C3-C7)carbocycle of Z1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z1a groups, wherein the Z1a groups are the same or different;
each Z1a is independently halogen or (C3-C7)carbocycle;
R2 is hydrogen or iodide;
R3 is (C1-C2)alkyl or 3-5 membered heterocycle, wherein the (C1-C2)alkyl is unsubstituted or substituted with 2 or 3 fluorine atoms;
R4 is hydrogen, —S(O)2—(C1-C2)alkyl, —S(O)2-cyclopropyl, or 5-membered heteroaryl, wherein any —S(O)2—(C1-C2)alkyl, —S(O)2-cyclopropyl, or 5-membered heteroaryl of R4 is unsubstituted or substituted with 1, 2, or 3 Z2 groups, wherein the Z2 groups are the same or different;
Z2 is (C1-C3)alkyl or cyclopropyl, wherein any (C1-C3)alkyl or cyclopropyl is unsubstituted or substituted with 1, 2, or 3 Z2a groups, wherein the Z2a groups are the same or different;
Z2a is hydroxyl or fluorine;
R5 is hydrogen, chorine, or fluorine; and
R6 is methyl.

### Claim 4 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein:
n is 0, 1, or 2;
m is 0 or 1;
each Z1 is independently (C1-C6)alkyl, (C3-C7)carbocycle, or halogen, wherein any (C1-C6)alkyl or (C3-C7)carbocycle of Z1 is unsubstituted or substituted with 1, 2, 3, 4 or 5 Z1a groups, wherein the Z1a groups are the same or different;
each Z1a is independently halogen or (C3-C7)carbocycle;
R2 is hydrogen;
R3 is (C1-C2)alkyl or 4-membered heterocycle, wherein the (C1-C2)alkyl is unsubstituted or substituted with 2 or 3 fluorine atoms;
R4 is —S(O)2—(C1-C2)alkyl, —S(O)2-cyclopropyl, or 5-membered heteroaryl, wherein any —S(O)2—(C1-C2)alkyl, —S(O)2-cyclopropyl, or 5-membered heteroaryl of R4 is unsubstituted or substituted with 1, 2, or 3 Z2 groups, wherein the Z2 groups are the same or different;
Z2 is (C1-C3)alkyl or cyclopropyl, wherein any (C1-C3)alkyl or cyclopropyl is unsubstituted or substituted with 1, 2, or 3 Z2a groups, wherein the Z2a groups are the same or different;
Z2a is hydroxyl or fluorine;
R5 is hydrogen, chorine, or fluorine; and
R6 is methyl.

### Claim 5 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein n is 1.

### Claim 6 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein m is 0.

### Claim 7 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is

### Claim 10 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is

### Claim 11 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is

### Claim 12 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is

### Claim 13 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R1 is

### Claim at position 14

-15. (canceled)

### Claim 16 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein Z1 is (C1-C6)alkyl substituted with 2 or 3 halogen atoms, a cyclopropyl group, or halogen.

### Claim at position 16

-18. (canceled)

### Claim 19 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R2 is hydrogen or iodide.

### Claim at position 18

-21. (canceled)

### Claim 22 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is (C1-C3)alkyl or a 4-membered heterocycle, wherein the (C1-C3)alkyl is unsubstituted or substituted with 1, 2, or 3 halogen atoms.

### Claim 23 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R3 is methyl, —CH2CHF2, —CH2CF3, or

### Claim 24

(canceled)

### Claim 25 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is hydrogen, —S(O)2—(C1-2)alkyl, —S(O)2-cyclopropyl, or an oxadiazole, wherein any —S(O)2—(C1-2)alkyl, —S(O)2-cyclopropyl, or oxadiazole of R4 is unsubstituted or substituted with 1, 2, or 3 Z2 groups, wherein the Z2 groups are the same or different.

### Claim 26

(canceled)

### Claim 27 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R4 is

### Claim at position 25

-29. (canceled)

### Claim 30 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, wherein R5 is hydrogen, chloride, or fluoride.

### Claim at position 27

-33. (canceled)

### Claim 34 (depends on 1)

The compound of claim 1, or a pharmaceutically acceptable salt thereof, which is

### Claim at position 29

-41. (canceled)

### Claim 42 (depends on 1)

A pharmaceutical composition comprising a compound of claim 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

### Claim 43

(canceled)

### Claim 44 (depends on 1)

A method for treating a HIV infection in a patient in need thereof comprising administering a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, to the patient.

### Claim 45 (depends on 1)

A method for treating an HIV infection in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of claim 1, or a pharmaceutically acceptable salt thereof, in combination with a therapeutically effective amount of an additional therapeutic agent, wherein the additional therapeutic agent is a HIV protease inhibitor, a HIV non-nucleoside or non-nucleotide inhibitor of reverse transcriptase, a HIV nucleoside or nucleotide inhibitor of reverse transcriptase, a HIV integrase inhibitor, a HIV non-catalytic site integrase inhibitor, an HIV entry inhibitor, an HIV maturation inhibitor, a latency reversing agent, a compound that targets the HIV capsid, an immune-based therapy, a phosphatidylinositol 3-kinase (PI3K) inhibitor, a HIV antibody, a bispecific antibody, an antibody-like therapeutic protein, a HIV p17 matrix protein inhibitor, a IL-13 antagonist, a peptidyl-prolyl cis-trans isomerase A modulator, a protein disulfide isomerase inhibitor, a complement C5a receptor antagonist, a DNA methyltransferase inhibitor, a HIV vif gene modulator, a Vif dimerization antagonist, a HIV-1 viral infectivity factor inhibitor, a TAT protein inhibitor, a HIV-1 Nef modulator, a Hck tyrosine kinase modulator, a mixed lineage kinase-3 (MLK-3) inhibitor, a HIV-1 splicing inhibitor, a Rev protein inhibitor, an integrin antagonist, a nucleoprotein inhibitor, a splicing factor modulator, a COMM domain containing protein 1 modulator, a HIV ribonuclease H inhibitor, a retrocyclin modulator, a CDK-9 inhibitor, a dendritic ICAM-3 grabbing nonintegrin 1 inhibitor, a HIV GAG protein inhibitor, a HIV POL protein inhibitor, a Complement Factor H modulator, a ubiquitin ligase inhibitor, a deoxycytidine kinase inhibitor, a cyclin dependent kinase inhibitor, a proprotein convertase PC9 stimulator, a ATP dependent RNA helicase DDX3X inhibitor, a reverse transcriptase priming complex inhibitor, a G6PD and NADH-oxidase inhibitor, a pharmacokinetic enhancer, a HIV gene therapy, or a HIV vaccine.

### Claim at position 34

-49. (canceled)
